The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)-Reference-Cited by-同舟云学术

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)

Published:2016-11-08 Issue:1 Volume:176 Page:76-85
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mesa Ruben¹,Vannucchi Alessandro M.²,Yacoub Abdulraheem³,Zachee Pierre⁴,Garg Mamta⁵,Lyons Roger⁶,Koschmieder Steffen⁷,Rinaldi Ciro⁸,Byrne Jennifer⁹,Hasan Yasmin¹⁰,Passamonti Francesco¹¹,Verstovsek Srdan¹²,Hunter Deborah¹³,Jones Mark M.¹³,Zhen Huiling¹³,Habr Dany¹⁴,Martino Bruno¹⁵

Affiliation:

1. Mayo Clinic Cancer Center; Scottsdale AZ USA

2. Center for Research and Innovation of Myeloproliferative Neoplasms; AOU Careggi; University of Florence; Florence Italy

3. University of Kansas Medical Center; Westwood KS USA

4. ZNA Stuivenberg; Antwerp Belgium

5. Leicester Royal Infirmary; Leicester UK

6. Texas Oncology and US Oncology Research; San Antonio TX USA

7. Department of Haematology, Oncology, Haemostaseology, and Stem Cell Transplantation; Faculty of Medicine; RWTH Aachen University; Aachen Germany

8. University of Lincoln and United Lincolnshire Hospital Trust; Lincoln UK

9. Nottingham University Hospitals; Nottingham UK

10. Sandwell and West Birmingham Hospitals NHS Trust; West Bromwich UK

11. University of Insubria; Varese Italy